NR 566 ADVANCED PHARMACOLOGY CARE OF THE FAMILY
MIDTERM EXAM 2026/2027 | Rated A | Latest Chamberlain
College Guide | Pass Guaranteed
Unit 1: Pharmacokinetics & Pharmacodynamics in Family Care (12 Questions)
Q1: A 78-year-old female with heart failure, chronic kidney disease (eGFR 35
mL/min/1.73m²), and atrial fibrillation presents for medication review. She currently
takes metoprolol succinate 50 mg daily, furosemide 40 mg daily, warfarin 5 mg daily
(INR therapeutic), and atorvastatin 40 mg daily. She reports increased fatigue and
dizziness over the past week. Her BP is 98/62 mmHg, HR 52 bpm. Which
pharmacokinetic principle best explains her current symptoms?
A. Decreased renal excretion causing drug accumulation and enhanced
pharmacodynamic effects
B. Increased hepatic metabolism due to age-related enzyme induction
C. Enhanced protein binding leading to increased free drug concentration
D. Increased gastric motility reducing drug absorption
Correct Answer: A
Rationale: The correct answer is decreased renal excretion causing drug accumulation
and enhanced pharmacodynamic effects [CORRECT]. This patient exhibits classic signs
of excessive beta-blockade (bradycardia, hypotension, fatigue, dizziness) likely from
metoprolol accumulation. Age-related decline in renal function (evidenced by eGFR 35)
reduces elimination of water-soluble drugs and active metabolites. Metoprolol is
metabolized hepatically, but its pharmacologically active metabolites are renally
excreted, and reduced renal perfusion from heart failure further compromises drug
clearance. Additionally, furosemide-induced volume contraction may exacerbate
hypotension through pharmacodynamic synergy with metoprolol.
,Option B is incorrect because aging typically reduces, not increases, hepatic
metabolism due to decreased liver mass and blood flow (20-40% reduction), not
enzyme induction. Option C is incorrect because aging reduces albumin and increases
alpha-1-acid glycoprotein, typically decreasing protein binding for acidic drugs, not
enhancing it; while this could increase free fraction, it doesn't explain the specific
bradycardia/hypotension pattern seen here. Option D is incorrect because aging
decreases gastric motility and acid production, potentially increasing (not decreasing)
drug absorption for some medications, but this doesn't explain the symptomatic
presentation of excessive drug effect.
Q2: A 28-year-old pregnant patient (32 weeks gestation) with epilepsy controlled on
valproic acid 1000 mg BID presents for prenatal care. Her seizure control has been
excellent, but recent trough levels show decreased concentrations despite adherence.
Which pharmacokinetic change in pregnancy best explains this finding?
A. Increased volume of distribution and increased hepatic metabolism
B. Decreased renal blood flow and reduced glomerular filtration
C. Reduced plasma protein binding and decreased cardiac output
D. Increased intestinal transit time and reduced absorption
Correct Answer: A
Rationale: The correct answer is increased volume of distribution and increased hepatic
metabolism [CORRECT]. Pregnancy induces significant pharmacokinetic changes:
plasma volume expands 40-50%, increasing volume of distribution for drugs, which
lowers plasma concentrations. Additionally, pregnancy induces hepatic CYP enzymes
(particularly CYP3A4, CYP2D6, CYP2C9) and increases renal blood flow/GFR by 50%,
enhancing drug clearance. Valproic acid undergoes extensive hepatic metabolism, and
the induction of metabolic enzymes during pregnancy increases clearance,
necessitating dose increases (typically 20-50%) to maintain therapeutic levels and
prevent breakthrough seizures.
,Option B is incorrect because pregnancy increases, not decreases, renal blood flow and
GFR. Option C is partially correct about reduced protein binding (albumin decreases in
pregnancy, increasing free fraction), but incorrect about decreased cardiac
output—cardiac output actually increases 30-50% during pregnancy. While reduced
binding could increase free drug, the dominant effect here is increased clearance from
expanded volume and induced metabolism. Option D is incorrect because pregnancy
typically reduces intestinal motility (increased transit time), which could theoretically
increase absorption, not reduce it; this doesn't explain decreased drug levels.
Q3: A 4-year-old child weighing 18 kg requires amoxicillin for acute otitis media. The
recommended dose is 80-90 mg/kg/day divided BID. The suspension available is 400
mg/5 mL. Which statement accurately describes the pharmacodynamic consideration
for this high-dose regimen?
A. High-dose amoxicillin achieves bactericidal killing through time-dependent
mechanisms requiring prolonged time above MIC
B. High-dose amoxicillin provides concentration-dependent killing where peak
concentration determines efficacy
C. High-dose amoxicillin works primarily through immunomodulatory effects rather than
antibacterial action
D. High-dose amoxicillin prevents resistance by inhibiting beta-lactamase production
Correct Answer: A
Rationale: The correct answer is high-dose amoxicillin achieves bactericidal killing
through time-dependent mechanisms requiring prolonged time above MIC [CORRECT].
Amoxicillin is a time-dependent antibiotic where efficacy correlates with the percentage
of the dosing interval that free drug concentrations exceed the minimum inhibitory
concentration (T>MIC), not peak concentration. High-dose amoxicillin (80-90
mg/kg/day) for acute otitis media targets penicillin-resistant Streptococcus
pneumoniae (PRSP) by increasing the probability that drug levels remain above the
, elevated MIC for resistant organisms throughout the dosing interval. The BID dosing
maintains therapeutic concentrations while improving adherence compared to TID
regimens.
Option B is incorrect because concentration-dependent killing characterizes
aminoglycosides and fluoroquinolones, not beta-lactams. Option C is incorrect because
while some antibiotics have immunomodulatory effects, amoxicillin's primary
mechanism is direct bacterial cell wall synthesis inhibition through penicillin-binding
proteins (PBPs). Option D is incorrect because amoxicillin does not inhibit
beta-lactamase production; beta-lactamase inhibitors like clavulanate are required for
beta-lactamase-producing organisms. High-dose therapy overcomes resistance through
pharmacodynamic optimization, not enzyme inhibition.
Q4: A 65-year-old male with type 2 diabetes, obesity (BMI 38), and nonalcoholic fatty
liver disease (NAFLD) is started on dulaglutide 0.75 mg weekly. After 8 weeks, his
HbA1c has decreased from 8.2% to 7.8%, but he reports persistent nausea and early
satiety. Which pharmacodynamic effect explains both the therapeutic benefit and the
adverse effect?
A. GLP-1 receptor agonism enhancing glucose-dependent insulin secretion and delaying
gastric emptying
B. DPP-4 inhibition increasing endogenous incretin levels and reducing hepatic glucose
output
C. SGLT2 inhibition promoting urinary glucose excretion and increasing gastrointestinal
motility
D. Amylin analog action suppressing glucagon secretion and accelerating gastric
emptying
Correct Answer: A
Rationale: The correct answer is GLP-1 receptor agonism enhancing glucose-dependent
insulin secretion and delaying gastric emptying [CORRECT]. Dulaglutide is a GLP-1
MIDTERM EXAM 2026/2027 | Rated A | Latest Chamberlain
College Guide | Pass Guaranteed
Unit 1: Pharmacokinetics & Pharmacodynamics in Family Care (12 Questions)
Q1: A 78-year-old female with heart failure, chronic kidney disease (eGFR 35
mL/min/1.73m²), and atrial fibrillation presents for medication review. She currently
takes metoprolol succinate 50 mg daily, furosemide 40 mg daily, warfarin 5 mg daily
(INR therapeutic), and atorvastatin 40 mg daily. She reports increased fatigue and
dizziness over the past week. Her BP is 98/62 mmHg, HR 52 bpm. Which
pharmacokinetic principle best explains her current symptoms?
A. Decreased renal excretion causing drug accumulation and enhanced
pharmacodynamic effects
B. Increased hepatic metabolism due to age-related enzyme induction
C. Enhanced protein binding leading to increased free drug concentration
D. Increased gastric motility reducing drug absorption
Correct Answer: A
Rationale: The correct answer is decreased renal excretion causing drug accumulation
and enhanced pharmacodynamic effects [CORRECT]. This patient exhibits classic signs
of excessive beta-blockade (bradycardia, hypotension, fatigue, dizziness) likely from
metoprolol accumulation. Age-related decline in renal function (evidenced by eGFR 35)
reduces elimination of water-soluble drugs and active metabolites. Metoprolol is
metabolized hepatically, but its pharmacologically active metabolites are renally
excreted, and reduced renal perfusion from heart failure further compromises drug
clearance. Additionally, furosemide-induced volume contraction may exacerbate
hypotension through pharmacodynamic synergy with metoprolol.
,Option B is incorrect because aging typically reduces, not increases, hepatic
metabolism due to decreased liver mass and blood flow (20-40% reduction), not
enzyme induction. Option C is incorrect because aging reduces albumin and increases
alpha-1-acid glycoprotein, typically decreasing protein binding for acidic drugs, not
enhancing it; while this could increase free fraction, it doesn't explain the specific
bradycardia/hypotension pattern seen here. Option D is incorrect because aging
decreases gastric motility and acid production, potentially increasing (not decreasing)
drug absorption for some medications, but this doesn't explain the symptomatic
presentation of excessive drug effect.
Q2: A 28-year-old pregnant patient (32 weeks gestation) with epilepsy controlled on
valproic acid 1000 mg BID presents for prenatal care. Her seizure control has been
excellent, but recent trough levels show decreased concentrations despite adherence.
Which pharmacokinetic change in pregnancy best explains this finding?
A. Increased volume of distribution and increased hepatic metabolism
B. Decreased renal blood flow and reduced glomerular filtration
C. Reduced plasma protein binding and decreased cardiac output
D. Increased intestinal transit time and reduced absorption
Correct Answer: A
Rationale: The correct answer is increased volume of distribution and increased hepatic
metabolism [CORRECT]. Pregnancy induces significant pharmacokinetic changes:
plasma volume expands 40-50%, increasing volume of distribution for drugs, which
lowers plasma concentrations. Additionally, pregnancy induces hepatic CYP enzymes
(particularly CYP3A4, CYP2D6, CYP2C9) and increases renal blood flow/GFR by 50%,
enhancing drug clearance. Valproic acid undergoes extensive hepatic metabolism, and
the induction of metabolic enzymes during pregnancy increases clearance,
necessitating dose increases (typically 20-50%) to maintain therapeutic levels and
prevent breakthrough seizures.
,Option B is incorrect because pregnancy increases, not decreases, renal blood flow and
GFR. Option C is partially correct about reduced protein binding (albumin decreases in
pregnancy, increasing free fraction), but incorrect about decreased cardiac
output—cardiac output actually increases 30-50% during pregnancy. While reduced
binding could increase free drug, the dominant effect here is increased clearance from
expanded volume and induced metabolism. Option D is incorrect because pregnancy
typically reduces intestinal motility (increased transit time), which could theoretically
increase absorption, not reduce it; this doesn't explain decreased drug levels.
Q3: A 4-year-old child weighing 18 kg requires amoxicillin for acute otitis media. The
recommended dose is 80-90 mg/kg/day divided BID. The suspension available is 400
mg/5 mL. Which statement accurately describes the pharmacodynamic consideration
for this high-dose regimen?
A. High-dose amoxicillin achieves bactericidal killing through time-dependent
mechanisms requiring prolonged time above MIC
B. High-dose amoxicillin provides concentration-dependent killing where peak
concentration determines efficacy
C. High-dose amoxicillin works primarily through immunomodulatory effects rather than
antibacterial action
D. High-dose amoxicillin prevents resistance by inhibiting beta-lactamase production
Correct Answer: A
Rationale: The correct answer is high-dose amoxicillin achieves bactericidal killing
through time-dependent mechanisms requiring prolonged time above MIC [CORRECT].
Amoxicillin is a time-dependent antibiotic where efficacy correlates with the percentage
of the dosing interval that free drug concentrations exceed the minimum inhibitory
concentration (T>MIC), not peak concentration. High-dose amoxicillin (80-90
mg/kg/day) for acute otitis media targets penicillin-resistant Streptococcus
pneumoniae (PRSP) by increasing the probability that drug levels remain above the
, elevated MIC for resistant organisms throughout the dosing interval. The BID dosing
maintains therapeutic concentrations while improving adherence compared to TID
regimens.
Option B is incorrect because concentration-dependent killing characterizes
aminoglycosides and fluoroquinolones, not beta-lactams. Option C is incorrect because
while some antibiotics have immunomodulatory effects, amoxicillin's primary
mechanism is direct bacterial cell wall synthesis inhibition through penicillin-binding
proteins (PBPs). Option D is incorrect because amoxicillin does not inhibit
beta-lactamase production; beta-lactamase inhibitors like clavulanate are required for
beta-lactamase-producing organisms. High-dose therapy overcomes resistance through
pharmacodynamic optimization, not enzyme inhibition.
Q4: A 65-year-old male with type 2 diabetes, obesity (BMI 38), and nonalcoholic fatty
liver disease (NAFLD) is started on dulaglutide 0.75 mg weekly. After 8 weeks, his
HbA1c has decreased from 8.2% to 7.8%, but he reports persistent nausea and early
satiety. Which pharmacodynamic effect explains both the therapeutic benefit and the
adverse effect?
A. GLP-1 receptor agonism enhancing glucose-dependent insulin secretion and delaying
gastric emptying
B. DPP-4 inhibition increasing endogenous incretin levels and reducing hepatic glucose
output
C. SGLT2 inhibition promoting urinary glucose excretion and increasing gastrointestinal
motility
D. Amylin analog action suppressing glucagon secretion and accelerating gastric
emptying
Correct Answer: A
Rationale: The correct answer is GLP-1 receptor agonism enhancing glucose-dependent
insulin secretion and delaying gastric emptying [CORRECT]. Dulaglutide is a GLP-1
